Encochleated amikacin - Matinas BioPharma

Drug Profile

Encochleated amikacin - Matinas BioPharma

Alternative Names: C-Amikacin; MAT 2501

Latest Information Update: 03 Apr 2017

Price : $50

At a glance

  • Originator Aquarius Biotechnologies
  • Developer Matinas BioPharma
  • Class Aminoglycosides; Antibacterials; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mycobacterial infections
  • New Molecular Entity No

Highest Development Phases

  • Phase I Mycobacterial infections
  • Preclinical Gram-negative infections

Most Recent Events

  • 29 Mar 2017 Matinas BioPharma plans a phase II trial for Mycobacterial infections (Non-tuberculous) in USA
  • 27 Mar 2017 Adverse events data from a phase I trial in Mycobacterial infections released by Matinas BioPharma
  • 27 Mar 2017 Matinas BioPharma completes a phase I trial in Mycobacterial infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top